Thermogenesis' Hemo-Matic blood collection monitor cleared by FDA:
This article was originally published in Clinica
Thermogenesis' Hemo-Matic blood collection monitor has been cleared by the FDA for marketing in the US. The monitor, priced at $3,500, is an automated blood weighing and mixing device for collecting blood donations.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.